1
|
Chauhan J, Cecon E, Labani N, Gbahou F, Real F, Bomsel M, Dubey KD, Das R, Dam J, Jockers R, Sen S. Development of indolealkylamine derivatives as potential multi-target agents for COVID-19 treatment. Eur J Med Chem 2023; 249:115152. [PMID: 36724633 PMCID: PMC9882955 DOI: 10.1016/j.ejmech.2023.115152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 01/18/2023] [Accepted: 01/23/2023] [Indexed: 02/03/2023]
Abstract
COVID-19 is a complex disease with short-term and long-term respiratory, inflammatory and neurological symptoms that are triggered by the infection with SARS-CoV-2. As many drugs targeting single targets showed only limited effectiveness against COVID-19, here, we aimed to explore a multi-target strategy. We synthesized a focused compound library based on C2-substituted indolealkylamines (tryptamines and 5-hydroxytryptamines) with activity for three potential COVID-19-related proteins, namely melatonin receptors, calmodulin and human angiotensin converting enzyme 2 (hACE2). Two molecules from the library, 5e and h, exhibit affinities in the high nanomolar range for melatonin receptors, inhibit the calmodulin-dependent calmodulin kinase II activity and the interaction of the SARS-CoV-2 Spike protein with hACE2 at micromolar concentrations. Both compounds inhibit SARS-CoV-2 entry into host cells and 5h decreases SARS-CoV-2 replication and MPro enzyme activity in addition. In conclusion, we provide a proof-of-concept for the successful design of multi-target compounds based on the tryptamine scaffold. Optimization of these preliminary hit compounds could potentially provide drug candidates to treat COVID-19 and other coronavirus diseases.
Collapse
Affiliation(s)
- Jyoti Chauhan
- Department of Chemistry, School of Natural Sciences, Dadri, Chithera, Gautam Buddha Nagar, UP, 201314, India
| | - Erika Cecon
- Université Paris Cité, Institut Cochin, INSERM, CNRS, F-75014, PARIS, France
| | - Nedjma Labani
- Université Paris Cité, Institut Cochin, INSERM, CNRS, F-75014, PARIS, France
| | - Florence Gbahou
- Université Paris Cité, Institut Cochin, INSERM, CNRS, F-75014, PARIS, France
| | - Fernando Real
- Université Paris Cité, Institut Cochin, INSERM, CNRS, F-75014, PARIS, France
| | - Morgane Bomsel
- Université Paris Cité, Institut Cochin, INSERM, CNRS, F-75014, PARIS, France
| | - Kshatresh Dutta Dubey
- Department of Chemistry, School of Natural Sciences, Dadri, Chithera, Gautam Buddha Nagar, UP, 201314, India
| | - Ranajit Das
- Department of Chemistry, School of Natural Sciences, Dadri, Chithera, Gautam Buddha Nagar, UP, 201314, India
| | - Julie Dam
- Université Paris Cité, Institut Cochin, INSERM, CNRS, F-75014, PARIS, France
| | - Ralf Jockers
- Université Paris Cité, Institut Cochin, INSERM, CNRS, F-75014, PARIS, France.
| | - Subhabrata Sen
- Department of Chemistry, School of Natural Sciences, Dadri, Chithera, Gautam Buddha Nagar, UP, 201314, India.
| |
Collapse
|
2
|
Jiang XL, Shen HW, Mager DE, Schmidt S, Yu AM. Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. Acta Pharm Sin B 2016; 6:492-503. [PMID: 27709018 DOI: 10.1016/j.apsb.2016.07.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Revised: 04/25/2016] [Accepted: 04/27/2016] [Indexed: 01/01/2023] Open
Abstract
We have shown recently that concurrent harmaline, a monoamine oxidase-A inhibitor (MAOI), potentiates serotonin (5-HT) receptor agonist 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)-induced hyperthermia. The objective of this study was to develop an integrated pharmacokinetic/pharmacodynamic (PK/PD) model to characterize and predict the thermoregulatory effects of such serotonergic drugs in mice. Physiological thermoregulation was described by a mechanism-based indirect-response model with adaptive feedback control. Harmaline-induced hypothermia and 5-MeO-DMT–elicited hyperthermia were attributable to the loss of heat through the activation of 5-HT1A receptor and thermogenesis via the stimulation of 5-HT2A receptor, respectively. Thus serotonergic 5-MeO-DMT–induced hyperthermia was readily distinguished from handling/injection stress-provoked hyperthermic effects. This PK/PD model was able to simultaneously describe all experimental data including the impact of drug-metabolizing enzyme status on 5-MeO-DMT and harmaline PK properties, and drug- and stress-induced simple hypo/hyperthermic and complex biphasic effects. Furthermore, the modeling results revealed a 4-fold decrease of apparent SC50 value (1.88–0.496 µmol/L) for 5-MeO-DMT when harmaline was co-administered, providing a quantitative assessment for the impact of concurrent MAOI harmaline on 5-MeO-DMT–induced hyperthermia. In addition, the hyperpyrexia caused by toxic dose combinations of harmaline and 5-MeO-DMT were linked to the increased systemic exposure to harmaline rather than 5-MeO-DMT, although the body temperature profiles were mispredicted by the model. The results indicate that current PK/PD model may be used as a new conceptual framework to define the impact of serotonergic agents and stress factors on thermoregulation.
Collapse
|
3
|
Abstract
This paper presents original research on prevalence, user characteristics and effect profile of N,N-dimethyltryptamine (DMT), a potent hallucinogenic which acts primarily through the serotonergic system. Data were obtained from the Global Drug Survey (an anonymous online survey of people, many of whom have used drugs) conducted between November and December 2012 with 22,289 responses. Lifetime prevalence of DMT use was 8.9% (n=1980) and past year prevalence use was 5.0% (n=1123). We explored the effect profile of DMT in 472 participants who identified DMT as the last new drug they had tried for the first time and compared it with ratings provided by other respondents on psilocybin (magic mushrooms), LSD and ketamine. DMT was most often smoked and offered a strong, intense, short-lived psychedelic high with relatively few negative effects or "come down". It had a larger proportion of new users compared with the other substances (24%), suggesting its popularity may increase. Overall, DMT seems to have a very desirable effect profile indicating a high abuse liability that maybe offset by a low urge to use more.
Collapse
Affiliation(s)
- Adam R Winstock
- 1Addiction CAG, South London and Maudsley NHS Trust, Southwark CDAT, London, UK
| | | | | |
Collapse
|
4
|
Wang S, Chen Y, Liu X, Xu X, Liu X, Liu BF, Zhang G. Synthesis and evaluation of novel 2,3-dihydrobenzo[b][1,4]dioxin- and indolealkylamine derivatives as potential antidepressants. Arch Pharm (Weinheim) 2013; 347:32-41. [PMID: 24214603 DOI: 10.1002/ardp.201300238] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2013] [Revised: 09/01/2013] [Accepted: 09/05/2013] [Indexed: 11/06/2022]
Abstract
A series of 2,3-dihydrobenzo[b][1,4]dioxin- and indolealkylamine derivatives were synthesized and the target compounds were evaluated for their binding affinities at the 5-HT1A receptor and serotonin transporter. Antidepressant-like activities of the compounds were screened using the tail suspension and forced swim tests in mice. Preliminary results indicated that the target compounds exhibited high binding affinities at the 5-HT1A receptor and serotonin transporter, and produced marked antidepressant-like effects. The best example from this study, compound 5, exhibited high binding affinities for the 5-HT1A receptor (Ki = 96 nM) and serotonin transporter (Ki = 9.8 nM). The intrinsic activity of compound 5 showed agonistic property to the 5-HT1A receptor and inhibition of the 5-HT transporter. Furthermore, compound 5 exhibited greater antidepressant efficacy than fluoxetine and showed acceptable pharmacokinetic properties.
Collapse
Affiliation(s)
- Songlin Wang
- Department of Biomedical Engineering, Systems Biology Theme, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China
| | | | | | | | | | | | | |
Collapse
|